Raltegravir and Disease progression - a phase IV clinical study of FDA data

Summary:

Disease progression is reported as a side effect among people who take Raltegravir (raltegravir), especially for people who are male, 40-49 old, have been taking the drug for 1 - 6 months also take Emtricitabine, and have Hiv infection.

The phase IV clinical study analyzes which people have Disease progression when taking Raltegravir. It is created by eHealthMe based on reports of 5,050 people who have side effects when taking Raltegravir from the FDA, and is updated regularly.

What is Raltegravir?

Raltegravir has active ingredients of raltegravir. eHealthMe is studying from 5,054 Raltegravir users. Check the latest studies of Raltegravir.

What is Disease progression?

Disease progression is found to be associated with 1,800 drugs and 2,255 conditions by eHealthMe. Check the latest studies of Disease progression.

On Jul, 27, 2026

5,050 people reported to have side effects when taking Raltegravir.
Among them, 38 people (0.75%) have Disease progression.

Could Raltegravir cause Disease progression?

Among these 38 people:

How long have people been on Raltegravir when they have Disease progression? *

What is the gender of people who have Disease progression when taking Raltegravir? *

female: 27.27 %
male: 72.73 %

What is the age of people who have Disease progression when taking Raltegravir? *

What are other drugs people take besides Raltegravir? *

Emtricitabine: 11 people, 28.95%
Etoposide: 8 people, 21.05%
Etravirine: 8 people, 21.05%
Cyclophosphamide: 8 people, 21.05%
Prednisone: 8 people, 21.05%
Sovaldi: 7 people, 18.42%
Sulfamethoxazole And Trimethoprim: 6 people, 15.79%
Cisplatin: 6 people, 15.79%
Cytarabine: 6 people, 15.79%
Darunavir: 6 people, 15.79%

What are other side effects people have besides Disease progression? *

Visual Acuity Reduced (reduced clearness of vision): 8 people, 21.05%
Uveitis (inflammation of the uvea): 8 people, 21.05%
Glomerulonephritis Membranous (nephritis with inflammation of the capillary loops in the renal glomeruli): 8 people, 21.05%
Drug Ineffective: 6 people, 15.79%
Renal Impairment (severely reduced kidney function): 6 people, 15.79%
Blindness: 5 people, 13.16%
Genital Herpes (herpes infection of genital): 4 people, 10.53%
Pancytopenia (medical condition in which there is a reduction in the number of red and white blood cells, as well as platelets): 2 people, 5.26%
Blood Hiv Rna Increased: 2 people, 5.26%
Colitis (inflammation of colon): 2 people, 5.26%

What are the existing conditions these people have? *

Hiv Infection: 17 people, 44.74%
Glomerulonephritis Membranous (nephritis with inflammation of the capillary loops in the renal glomeruli): 8 people, 21.05%
Acquired Immunodeficiency Syndrome (disease of the human immune system caused by the human immunodeficiency virus (hiv)): 7 people, 18.42%
Lymphoma Aids Related (cancer of lymph system with aids): 6 people, 15.79%
Epstein-Barr Virus Associated Lymphoma (epstein-barr virus associated tumour): 6 people, 15.79%
Uveitis (inflammation of the uvea): 3 people, 7.89%
Transitional Cell Carcinoma (cancer tumour inner most layer of urinary system): 2 people, 5.26%
Adult T-Cell Lymphoma/leukaemia (cancer of the immune system's own t-cells): 2 people, 5.26%
Tuberculosis (a bacterial infection by mycobacterium tuberculosis): 1 person, 2.63%
Primary Effusion Lymphoma (large b-cell cancer): 1 person, 2.63%

* Approximation only. Some reports may have incomplete information.

Do you take Raltegravir and have Disease progression?

- Check whether Disease progression is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Raltegravir:

Raltegravir (5,054 reports)

Browse all side effects of Raltegravir:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Disease progression:

Disease progression (1,800 drugs)

Browse all the conditions that are associated with Disease progression:

Disease progression (2,255 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on raltegravir (the active ingredients of Raltegravir) and Raltegravir (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.